Bristol-Myers Squibb Company (TSX:BMY)
Canada · Delayed Price · Currency is CAD | Market Cap | 177.03B +32.4% |
| Revenue (ttm) | 71.03B +4.2% |
| Net Income | 13.12B +53.1% |
| EPS | 1.67 +51.9% |
| Shares Out | n/a |
| PE Ratio | 13.58 |
| Forward PE | 9.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,882 |
| Open | 22.75 |
| Previous Close | 23.06 |
| Day's Range | 22.72 - 22.75 |
| 52-Week Range | 22.36 - 23.59 |
| Beta | 0.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About TSX:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
News
Bristol Myers presents 56-week data from Phase 3 SCOUT-HCM clinical trial
Bristol Myers (BMY) Squibb presented 56-week results from the Phase 3 SCOUT-HCM clinical trial in a late-breaker presentation at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions, ta...
Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos.
Bristol Myers Squibb put volume heavy and directionally bearish
Bearish flow noted in Bristol Myers (BMY) Squibb with 8,291 puts trading, or 3x expected. Most active are 11/6 weekly 60 puts and 11/6 weekly 59 puts, with total volume…
Bristol Myers Squibb put volume heavy and directionally bearish
Bearish flow noted in Bristol Myers (BMY) Squibb with 9,343 puts trading, or 3x expected. Most active are 11/13 weekly 60 puts and 11/6 weekly 62 puts, with total volume…
3 of the Best Dividend Stocks to Own
These dividend stocks with economic moats offer durable payouts.
Bristol Myers price target lowered to $40 from $41 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Bristol Myers (BMY) to $40 from $41 and keeps an Underweight rating on the shares.
Bristol Myers price target lowered to $60 from $65 at Wells Fargo
Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Bristol Myers (BMY) to $60 from $65 and keeps an Equal Weight rating on the shares. The firm sees…
How Bristol Myers's CEO Challenged the Company's Managers
When Alan and I talked with Chris Boerner recently, a critical aspect of his leadership style was apparent immediately: He confronts issues head on.
Bristol-Myers Squibb Company Earnings Call Transcript: Q3 2026
Q3 revenue rose 7% and growth portfolio sales grew 12%, prompting higher FY 2026 guidance. Pipeline readouts and launches advanced, while the 2027 ELIQUIS LOE remains a significant headwind.
Bristol-Myers Squibb Company Earnings release: Q3 2026
Bristol-Myers Squibb Company released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Bristol-Myers Squibb Company Slides: Q3 2026
Bristol-Myers Squibb Company has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Bristol-Myers Squibb Company Quarterly report: Q3 2026
Bristol-Myers Squibb Company has published its Q3 2026 quarterly earnings report on October 29, 2026.
Bristol Myers Squibb Raises Outlook as Quarterly Revenue Rises
Bristol Myers Squibb raised its full-year revenue outlook due to higher third-quarter revenue.
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Bristol Myers Squibb raised its full-year revenue forecast on Thursday, citing strong sales of its newer medicines, but lowered its 2026 earnings per share projection due to a hefty acquisition-relat...
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2026.
Bristol Myers price target lowered to $78 from $82 at Piper Sandler
Piper Sandler lowered the firm’s price target on Bristol Myers (BMY) to $78 from $82 and keeps an Overweight rating on the shares. The firm is reviewing the Q3 cycle…
Bristol Myers, SystImmune announce results from Phase 3 study of iza-bren
SystImmune and Bristol Myers (BMY) Squibb announced that SystImmune’s parent company Sichuan Biokin reported positive results from a prespecified interim analysis in the randomized, multicenter Phase ...
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small...
BioNTech, Bristol Myers announces data from Phase 2 ROSETTA Lung-107 trial
BioNTech (BNTX) and Bristol Myers Squibb Company (BMY) announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific imm...
Bristol Myers tells Bloomberg aims to resume paused CAR-T trials in 2027
A Bristol Myers (BMY) spokesperson stated in an email to Bloomberg that the company has identified the cause of an earlier-observed CAR-T safety signal and that the company aims to…
Bristol Myers discloses death of CAR T patient in MS study
Bristol Myers (BMY) disclosed that one patient with highly active relapsing multiple sclerosis experienced a fatal event of septic pneumonia in its Phase 1 trial. Following zola-cel infusion, the pati...
Bristol Myers presents results from Phase 1 Breakfree-2 study
Bristol Myers (BMY) Squibb announced disclosure of interim safety and efficacy results from the multiple sclerosis cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2 study evaluating zola...
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients.
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology ...
Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
NEW YORK--(BUSINESS WIRE)--Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing...